Please ensure Javascript is enabled for purposes of website accessibility

Good Luck in 2010, Merck

By Brian Orelli, PhD - Updated Apr 5, 2017 at 8:04PM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

Next year isn't looking so hot.

Wow, what a difference a year makes.

Last year, I wrote about how laughable it was that Merck (NYSE:MRK) put out conservative guidance of just a 7% increase in adjusted earnings per share at the midpoint of the range.

Now, nobody is laughing. It looks like Merck will just barely make the range it set out last year, and the company has guided for potentially lower adjusted earnings next year.

It's not just one problem for Merck, but a series of issues that have turned the company into a heap of stale drugs. Cholesterol-lowering drugs Vytorin and Zetia, marketed with Schering-Plough (NYSE:SGP), are still languishing from the Enhance data and probably won't see a major turnaround until the duo gets some data proving that the drugs decrease cardiac events, not just cholesterol levels.

Growth in sales of Merck's human papillomavirus (HPV) vaccine, Gardasil, has stalled as well. Sales are expected to be flat next year, assuming the company can get the vaccine approved for older women and to protect males from warts. That also assumes that GlaxoSmithKline's (NYSE:GSK) Cervarix doesn't take more of a bite out of Merck's monopoly in the U.S. should Cervarix get approved next year.

The bigger problem for Merck is that it doesn't have anything to get the revenue growth back on track. The FDA turned down cholesterol drug MK-0524A, and now it won't be on the market until 2013 at the earliest. And development of its potential-blockbuster diet drug, taranabant, got canned after a phase 3 trial showed that, like Sanofi-Aventis' (NYSE:SNY) Acomplia/Zimulti, the drug also caused psychiatric problems.

Maybe the company should use some of its $6.8 billion in cash and investments to buy some new drugs, much like Eli Lilly (NYSE:LLY) has done or Pfizer (NYSE:PFE) might be considering. Without that, I'm having trouble seeing how Merck will increase in the next few years. However, current investors aren't in a horrible position, either. With the substantial share-price drop so far this year, investors are now getting paid a whopping 6.1% dividend yield to wait on top of the trash heap.

Glaxo, Lilly, and Pfizer are all Income Investor recommendations. To see how dividend-paying stocks can offer both secure income and the opportunity for growth, take a free look at this newsletter service with a 30-day free trial. 

Fool contributor Brian Orelli, Ph.D., doesn't own shares of any company mentioned in this article. Pfizer is also an Inside Value choice, and the Fool owns shares. The Fool has a disclosure policy.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

Merck & Co., Inc. Stock Quote
Merck & Co., Inc.
$91.04 (0.50%) $0.45
Eli Lilly and Company Stock Quote
Eli Lilly and Company
$316.82 (2.10%) $6.51
Sanofi Stock Quote
$42.18 (-5.87%) $-2.63
Pfizer Inc. Stock Quote
Pfizer Inc.
$49.27 (-1.18%) $0.59
GSK Stock Quote
$34.70 (-1.59%) $0.56

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning analyst team.

Stock Advisor Returns
S&P 500 Returns

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 08/17/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.